Maintenance Trial by Orencia in Rheumatoid Arthritis

Maintenance Trial by Orencia in Rheumatoid Arthritis - MATADOR Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010286

Enrollment

150

Registered

2013-03-21

Start date

2013-03-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Patients whose RA status is in low disease activity after 24 weeks of treatment with abatacept receive the reduced dosage of abatacept.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Aged 20 years or over at given IC 2.Fullfill the 1987ACR classification criteria or ACR/EULAR2010 criteria for RA 3.Patients who received abatacept for more than 24 weeks and have low disease activity 4.Patients who give full consent to this study

Exclusion criteria

Exclusion criteria: 1. Patients contraindicated with abatacept 2. Patients more than 125 kg in weight 3. Patients considered ineligible for this study for any reason by the attending physician

Design outcomes

Primary

Measure	Time frame
Continuance rate of patients receiving a reduced dose of abatacept after 1 year	—

Secondary

Measure	Time frame
1.SDAI,CDAI,DAS28 at 1 year 2.TSS at 1 year 3.HAQ-DI at 1 year 4.Joint Ultrasonography at 1 year	—

Countries

Japan

Contacts

Public ContactShinsuke Yasuda

Hokkaido University Hospital Department of Internal Medicine 2

syasuda@med.hokudai.ac.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026